HEALTHglobal
Weight-loss drug semaglutide does not slow Alzheimer's disease, two clinical trials find
Single source
Updated 2 hours ago
First seen March 21, 2026 08:33:05Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the first large Phase III randomized controlled trials on the topic published in The Lancet.